Research programme: liposomal nucleic acid therapeutics - Bio-Path Holdings

Drug Profile

Research programme: liposomal nucleic acid therapeutics - Bio-Path Holdings

Alternative Names: BP-100-1.02; BP-100-2.01; BP-1002; Liposomal Bcl-2; Liposomal Bcl2 antisense

Latest Information Update: 04 Jul 2016

Price : $50

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer Bio-Path Holdings
  • Class Antisense RNA; Small interfering RNA
  • Mechanism of Action Focal adhesion protein-tyrosine kinase inhibitors; Proto-oncogene protein c-bcl-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic myeloid leukaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Follicular lymphoma; Solid tumours

Most Recent Events

  • 15 Mar 2017 Bio-Path Holdings plans a phase I trial of BP 100 1.02 for Lymphoma (Bio-Path Holdings pipeline, March 2017)
  • 15 Mar 2017 Bio-Path Holdings plans clinical trials of BP 100 1.02 for Solid tumours
  • 28 Jun 2016 Bio-Path enters into a sponsored research agreement with Thomas Jefferson University to investigate DNAbilize antisense DNA technology for the development of Brain cancer vaccine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top